FY2022 Earnings Estimate for Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Issued By Zacks Investment Research

Emmaus Life Sciences, Inc. (OTCMKTS:EMMAGet Rating) – Stock analysts at Zacks Investment Research lowered their FY2022 earnings per share (EPS) estimates for Emmaus Life Sciences in a research note issued to investors on Monday, May 16th. Zacks Investment Research analyst B. Sorensen now anticipates that the company will post earnings of $0.00 per share for the year, down from their prior estimate of $0.04.

Shares of OTCMKTS EMMA opened at $0.40 on Thursday. Emmaus Life Sciences has a 1 year low of $0.25 and a 1 year high of $4.00. The firm’s 50-day moving average is $0.90 and its 200-day moving average is $1.26.

Emmaus Life Sciences (OTCMKTS:EMMAGet Rating) last issued its quarterly earnings data on Friday, May 13th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.04).

Emmaus Life Sciences Company Profile (Get Rating)

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Featured Articles

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.